Sinorise Pharchem Co., Ltd

Company Details

  • Business Type : Trading Company
  • Location : Guangdong
  • Year Established : 2006
  • Number Of Employees : 51 - 100
  • Export Percentage :
  • Production Lines :
  • R&D Staff :
  • Total Annual Revenue :
  • Main Products : Anti-cancer, Antiobesity, Antidiabetics,Antiviral,Antineoplastic,Cardiovascular,Antibiotics,Peptides,Hormones Api Intermediates,
  • Country/Region : China
  • Links : China Chemicals, China Pharmaceutical Chemicals,
  • Company Introduction

    Sinorise Pharchem Co., Ltd is one of the professional companies, which is committed to R&D, production, and marketing of APIs and pharmaceutical intermediates with headquarter in Wuhan. We have some GMP facilities and cooperative factories in Hubei, Zhejiang, Jiangsu and Shandong Province. The products range covering antineoplastic, cardiovascular, antiviral, antibiotics, antidiabetics, peptides, ect. With advanced and excellent technology, professional and high efficient service, and sustained effort of the whole staff, our company develops rapidly. Our products are well sold to more than 50 countries and areas. Moreover, we built good and long relations with many big pharmaceutical companies worldwide. We always adhere to customer demand-oriented, and supply customers with high quality products and service. We sincerely welcome suppliers and customers worldwide to consult and seek mutual cooperation and development.

    Company Information

  • Contact Person : Ruth Liu
  • Job Title : Sales
  • Telephone :
  • Fax Number :
  • Address : Dongxihu District Shenzhen, Guangdong
  • Fax : 86 - -
  • Website : Visit website
  • Company Product

    • Atazanavir Intermediates
    • Atorvastatin Intermediates
    • Betamethasone
    • Daclatasvir.2HCL Intermediates
    • Darunavir Intermediates
    • Dexamethasone Sodium Phosphate
    • Glimepiride Intermediates
    • Ledipasvir Intermediates
    • Moxifloxacin Intermediates
    • Rosuvastatin Intermediates
    • Teneligliptin Intermediates
    • sofosbuvir Intermediates